Gilead Raday insider trades: RedHill Biopharma (RDHL) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Gilead reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | RDHL | ↓ Sell | 14,310,000 | $0.00 | $1K | Direct | Oct 6, 2026 (5d) |
| Apr 6, 2026 | RDHL | ↓ Sell | 15,740,000 | $0.00 | $2K | Direct | Apr 22, 2026 (16d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Gilead Raday's insider trades
Gilead Raday is Chief Operating Officer at RedHill Biopharma (RDHL). Since Apr 6, 2026, Gilead has reported no open-market purchases and 2 sales worth $3K on SEC Form 4. In the last 12 months: 2 sales ($3K).
Their filings also include option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RDHL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.